Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Symbotic (SYM) jumped 17.5% on its $200M acquisition ... FY2025 revenue guidance over weaker-than-expected demand for its COVID and RSV vaccines. Plug Power (PLUG) dropped nearly -14% in a week ...

Amid criticism by Opposition parties, the Bhartiya Janata Party has presented a comprehensive report on India's economy. The party has pushed back against allegations of economic mismanagement and ...

Here’s the latest on symptoms, treatments and testing. By Dani Blum Dani Blum has reported on Covid since the spring of 2020. There are few constants when it comes to Covid, but one thing has ...

GBS, a neurological condition triggered by an overactive immune system often after viral or bacterial infections, has been ...

Investors looking for stocks in the Technology Services sector might want to consider either Futu Holdings Limited Sponsored ADR (FUTU) or Symbotic Inc. (SYM). But which of these two stocks ...

In this article, we are going to take a look at where Symbotic Inc. (NASDAQ:SYM) stands against the other stocks. A lackluster trading persisted throughout Thursday, with Wall Street’s main ...

Covid-19 is now ubiquitous – but hospitalisations seem to be on a downward trajectory. No one knows why. When virologists took their first peek at XEC, the Covid-19 variant which started to ...

Reports of rising cases of a flu-like illness in China, where COVID-19 was first detected five years ago, sparked international concerns about the potential for another worldwide pandemic.

With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. Experts expect cases to rise again this winter.